Medical Oncology 1

A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-delet

A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer n. MK6070-003

A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Solid Tumors (Master Protocol)

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Participants with Metastatic Squamous NSCLC (INTerpath-013)

A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-31

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoa

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negativ

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With

A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced

A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Squamous Solid Tumors

A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors

A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WI

A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of inavolisib in combination with phesgo versus placebo in combination with phesgo as maintenance therapy af

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INAVOLISIB COMBINED WITH A CDK4/6 INHIBITOR AND LETROZOLE VERSUS PLACEBO COMBINED WITH A CDK4/6 INHIBITO

A phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a cdk4/6 inhibitor, in patients with estrogen receptor-positive, her2-negative advanc

A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD-BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTSIT

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab
Deruxtecan Monotherapy versus Treatment of Physician’s Choice in
Hormone Receptorpositive, HER2-negative Unresectable Locally Advanced or
Metastatic Br

Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours.

FASTing-like approach to improve the efficacy of maintenance IMMunotherapy in Extensive-stage small cell lung cancer patients not progressing on chemoimmunotherapy induction: the FASTIMMUNE trial.

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as
Monotherapy and in Combination With Other Antineoplastic Agents in
Participants With Advanced Solid Tumors

Targeting triple negative BREAst cancer metabolism with a combination of chemoimmunotherapy and a FASTing-like approach in the preoperative setting: the BREAKFAST 2 trial.